

Response: Fospropofol: Pharmacokinetics?

Sir,

The pharmacokinetic and pharmacodynamic results of liberated propofol published by Shah *et al.* could be inaccurate.^[1] They have mentioned in their article that they would carry out studies using appropriate assay methods to assess the same and find the degree of error within a period of 12 months. They have not been able to publish the new data and six previously published articles have been retracted.^[1] The assay inaccuracy is limited to propofol kinetics only, and therefore, previously published fospropofol kinetics are unaffected.^[2]

Time to achieve C_{max} of liberated propofol at 12 and 8 min, the volume of distribution of liberated propofol 5.8 l/kg, and the mean terminal phase half life of 2.06 ± 0.77 h for propofol, described in pharmacokinetics in our article,^[3] may be inaccurate. Three references (Schywalsky *et al.*,^[4] Fechner *et al.*,^[5] and Gibiansky *et al.*^[6]) in our review article^[3] have been retracted. Pharmacokinetic data of liberated propofol have been quoted by us from Gibiansky *et al.* only. We wish to bring to your notice that US FDA approval label for fospropofol as on 21-01-2010, which was accessed by the authors on 17-08-2010 and 30-09-2011, about the pharmacokinetics of liberated propofol has not changed till date.^[7]

**Girish M Bengalorkar, Bhuvana K, Sarala N, TN
Kumar**

Department of Pharmacology, Sri Devaraj Urs Medical College,
Tamaka, Kolar, Karnataka, India

Address for correspondence: Dr. Girish M Bengalorkar,
Department of Pharmacology, Sri Devaraj Urs Medical College,
Tamaka, Kolar, Karnataka, India
E-mail: drbengoboy@gmail.com

References

1. Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. *Anesth Analg* 2009;108:382.
2. Mueller SW, Moore GD, MacLaren R. Fospropofol Disodium for Procedural Sedation: Emerging Evidence of its Value? *Clinical Medicine Insights: Therapeutics* 2010;2:513-22.
3. Bengalorkar GM, Bhuvana K, Sarala N, Kumar TN. Fospropofol: Clinical Pharmacology. *J Anaesth Clin Pharmacol* 2011;27:79-83.
4. Schywalsky M, Ihmsen H, Tzabazis A, Fechner J, Burak E, Vornov J, *et al.* Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. *Eur J Anaesthesiol* 2003;20:182-90.
5. Fechner J, Ihmsen H, Hatterschild D, Jeleazcov C, Schiessl C, Vornov JJ, *et al.* Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.

Letters to the Editor

- Anesthesiology 2004;101:626-39.
- Gibiensky E, Struys MM, Gibiinsky L, Vanluchene AL, Vornov J, Mortier EP, *et al.* AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN, part 1: Pharmacokinetics [published correction appears in *Anesthesiology* 2008;109:940]. *Anesthesiology* 2005;103:718-29.
 - Lusedra (fospropofol disodium) US prescribing information [online]. Available from URL: <http://www.accessdata.fda.gov> [Last accessed on 2011 Sep 30]

| Access this article online | |
|---|--|
| Quick Response Code: | Website: www.joacp.org |
|  | DOI: 10.4103/0970-9185.92473 |